Arena Pharmaceuticals EBIT

Arena Pharmaceuticals (ARNA) currently reports a EBIT of $-550M as of December 2021. That compares with $-430M in the prior-year period — down 29.4% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Arena Pharmaceuticals's EBIT history and peer comparisons.

Arena Pharmaceuticals's EBIT decreased from $-430M to $-550M — a 29.4% year-over-year decrease (period ending December 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arena Pharmaceuticals's EBIT of $-550M is lower than the Healthcare sector average of $23B. That is roughly 102.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Arena Pharmaceuticals reported $-550M in EBIT as of December 2021. That compares with $-430M in the prior-year period — down 29.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-550M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Arena Pharmaceuticals, and consider following ARNA for alerts when major investors trade the stock.